hero image
Peter Gulick, DO FACP, FIDSA, FACOI - Michigan State University. East Lansing, MI, US


Professor of Medicine | Michigan State University


Take care of HIV/AIDS patients as well as Hepatitis C, B patients at 3 sites in Michigan






loading image




Peter Gulick is currently an associate professor of medicine at Michigan State University, College of Osteopathic Medicine, and serves as adjunct faculty in the College of Human Medicine and the College of Nursing.

He received training in two primary specialties: infectious diseases at the Cleveland Clinic Foundation and medical oncology at Roswell Park Memorial Institute.

Gulick is director of the MSU HIV/Hepatitis clinic where his primary area of interest is HIV therapy, as well as hepatitis B, hepatitis C and co-infection therapy.

In addition to teaching, Gulick has cared for HIV patients for 20 years and hepatitis C patients for 10 years.

He has served on the Lung Cancer Advisory Committee through the State of Michigan's Department of Community Health , as well as the HIV/AIDS Prevention and Intervention Section, the Michigan Cancer Consortium and the Region 1 Smallpox Planning Team.

Industry Expertise (3)

Writing and Editing



Areas of Expertise (3)

Hepatitis C


Hepatitis B

Education (7)

Cleveland Clinic Foundation: Infectious Diseases 1983

Roswell Park Memorial Institute: Medical Oncology 1981

Cleveland Clinic Foundation: Internal Medicine 1980

Detroit Osteopathic Hospital: Internship 1977

Midwestern University: D.O. 1976

Michigan State University: M.D.

University of Michigan,: M.A., Health Managements and Policy

News (10)

Infectious disease expert praises vaccination rate

WKAR  online


With the number of people vaccinated against coronavirus growing daily, people in Michigan are starting to wonder about life after getting their shots. WKAR's Scott Pohl talks with Peter Gulick, an expert in infectious diseases at Michigan State University. Gulick is impressed with the pace of vaccinations. “There's a lot of resources, I think, to get people vaccinated. Now, it's not as restricted as it was before. As far as around the country, it depends on the state you're in and what requirements they have, and what issues they have, but I think that we still have a long way to go. I think we still have to really promote and push vaccines and try to get them implemented as effectively as possible.”

view more

What does COVID-19 vaccine efficacy mean?

Verywell Health  online


Peter Gulick, associate professor of medicine at Michigan State University, tells Verywell that everyone should get the vaccine in order to decrease overall levels of the virus. “Just get vaccinated because the more people that get vaccinated, the closer we'll get to herd immunity,” Gulick says. Gulick explains that despite getting the vaccine, people may still transmit it to others. “Patients that get the vaccine may still be able to colonize," Gulick says. "They may have the virus up in their nose and it may not cause them disease where they feel symptoms." Because the disease might still be transmitted even after vaccination, Gulick recommends people continue wearing a mask, social distancing, and washing their hands regularly.

view more

Who should get the Johnson & Johnson vaccine over the mRNA vaccines?

Live Science  online


While the Moderna and Pfizer two-shot regimens look, on paper, to be more efficacious, the Johnson & Johnson vaccine has an edge because it doesn't require a follow-up shot and it can be stored at ordinary refrigerator temperatures for months, said Peter Gulick, a professor of medicine and an infectious disease expert at Michigan State University College of Osteopathic Medicine. That could help with getting more people vaccinated especially those who may not come back for a second shot, as well as in locales where access is a problem, he said. The Johnson & Johnson shot's less stringent storage requirements could be an advantage in rural areas, Gulick said. "They can be put in a refrigerator and stored there, whereas Moderna, and definitely Pfizer, need much colder temperatures to keep their vaccine viable," Gulick told Live Science.

view more

Arm pain after COVID-19 vaccine common

MedShadow  online


“The most common symptom patients are getting from these injections is pain. That's about 70% of the time,” says Peter Gulick, an associate professor of medicine at Michigan State University. He adds that his own arm was sore after he received the first shot of the Pfizer vaccine, but not after the second. Now, as more and more people are getting their shots, we're hearing details and personal stories, and a trend is emerging. Our vaccine side effect tracker has amassed more than 100 comments, many of which describe varying degrees of arm pain after the COVID-19 vaccine, along with redness, itching and swelling at the injection site.

view more

MSU Infectious Disease Specialist Weighs In On Pfizer COVID-19 Vaccine Announcement

WKAR  online


The drug manufacturer Pfizer announced promising test results on a possible COVID-19 vaccine this week. It’s being reported that the vaccine could be submitted to the FDA for emergency use authorization as soon as the third week of November. WKAR’s Scott Pohl talks with MSU infectious disease specialist Dr. Peter Gulick about the Pfizer announcement.

view more

Preflight Covid-19 testing is on the rise — the question is whether it works

CNBC  online


In calling for preflight testing last month, the IATA said that, “deployable solutions are expected in the coming weeks.” Medical experts say that may be premature. Polymerase chain reaction tests, also called PCR, can more accurately diagnose positive cases, said Dr. Peter Gulick, an infectious disease expert at Michigan State University. But those tests, which rely on a nasal swap, throat swab or saliva, “are run in a lab so it may take days to come back, and a patient may get infected during that time,” he said. That is the rub with PCR tests. Test too early, and a person’s chances of being infected after the test increase. Test too late, and the results may not be ready by departure time.

view more

We Asked Doctors to Weigh In on the Biggest Coronavirus Myths Circulating Right Now

Yahoo! Finance  online


FACT: Even if you don't have symptoms, you can still be contagious. “It's possible that 70% to 80% of people may have mild to no symptoms, but I would still be very cautious because you may still be infectious,” says Peter Gulick, infectious disease expert at Michigan State University. What common symptoms should you expect? That landscape changes by the day, but as of now a high fever, dry cough, shortness of breath, and loss of sense of smell or taste are biggies to look out for. Some people are also thought to exhibit gastrointestinal signs like diarrhea, body aches, and upper respiratory symptoms like congestion. Keep yourself healthy by washing your hands regularly and staying inside.

view more

Should You Invest in a UV Light to Sanitize Surfaces Like Your Phone? We Asked Experts

Pop Sugar  online


Does UV Light Actually Kill the Coronavirus? Peter Gulick, associate professor of medicine at Michigan State University, said that, while ultraviolet Cis the most effective form of UV light for combatting pathogens, "it's also potentially toxic to skin and mucous membranes."

view more

Michigan has over 100,000 confirmed cases of coronavirus

Detroit Free Press  online


Michigan surpassed 100,000 confirmed coronavirus cases Friday. According to Peter Gulick, an infectious disease specialist and associate professor of medicine at Michigan State University, the state may need to prepare for 100,000 additional new cases by mid-January. "Nothing has changed as far as the virus goes," Gulick said to the Detroit Free Press earlier this month. "We have nothing beyond what we had in March (to treat it or prevent it). So, we still have to go by the old principles: Wear face masks, social distancing, don't go into crowds."

view more

Michigan marks 100K coronavirus cases in 5 months. Experts warn we'll see at least 100K more

Detroit Free Press  online


By most measures, Michigan has managed to contain the spread better than many other states in a country that leads the world with 5.3 million cases and more than 168,000 deaths, according to the Johns Hopkins COVID-19 Global Case Tracker. But it's nowhere near over yet. The state should prepare to see another 100,000 new cases in the next five months, said Peter Gulick, an infectious disease specialist and associate professor of medicine at Michigan State University. "We'll be at more than 100,000" additional new coronavirus cases by mid-January, he predicted. "Nothing has changed as far as the virus goes," Gulick said. "We have nothing beyond what we had in March (to treat it or prevent it). So, we still have to go by the old principles: Wear face masks, social distancing, don't go into crowds."

view more

Research Focus (1)

Translational HIV Research

I have a MSU Registry of over 500 HIV patients with protected data for HIV research. There are currently 2 HIH grants for HIV research. We also do Pharmaceutical sponsored Drug trials on New HIV medication.